Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
To evaluate the absorption, distribution, metabolism and excretion (ADME) of single dose \[14C\] selumetinib in volunteers
Solid Tumours
DRUG: [C14] selumetinib (oral)
Concentration of total radioactivity in blood and plasma and percentage of radioactive dose in urine and faeces and total balance, Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days
Metabolite profiling and identification in plasma and excreta, Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days.|Pharmacokinetic parameters of selumetinib, Cmax, tmax, tÂ½, AUC, CL/F, Vz/F, MRT, fe, Ae, CLR, Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days.|Plasma concentrations of selumetinib, Samples collected prior to treatment, during treatment and follow-up for a maximum of 14 days|Safety, Adverse events, vital signs, electrocardiogram, haematology, clinical chemistry, urinalysis, physical examination, left ventricular ejection fraction, and opthalmology assessments., Assessments prior to treatment and after treatment including follow up.
To evaluate the absorption, distribution, metabolism and excretion (ADME) of single dose \[14C\] selumetinib in volunteers